Tsumura & Co.
【Tsumura】2026 Earnings Results | Sales: 192.6 billion yen (+6.4%)
Tsumura achieved sales of 192.6 billion yen (up 6.4% YoY) in the fiscal year ending March 2026, driven by the recovery from infectious disease outbreaks and expansion of the China business. Operating profit decreased to 3.52 billion yen (△12.2%), and net income attributable to owners of the parent declined to 2.81 billion yen (△13.3%). For the current term, an increase of 147 yen in dividends is planned.
Key Figures
- Sales: 192.6 billion yen (+6.4% YoY)
- Net income attributable to owners of the parent: 2.81 billion yen (△13.3%)
- Dividends: 147 yen (increase)
AI要約
Performance Overview
Tsumura recorded sales of 192.6 billion yen (up 6.4% YoY) in the fiscal year ending March 2026, achieving revenue growth through expansion of domestic and international operations. Sales in China increased by 52.4%, contributing to the overall sales increase. Meanwhile, operating profit and net income declined due to the easing of infectious disease outbreaks and inventory adjustments. Factors include expanded sales of medical Chinese herbal medicines and healthcare products domestically, as well as growth in the Chinese market. Dividends were increased to 147 yen, strengthening shareholder returns.
Future Outlook and Impact on Shareholders
For the fiscal year ending March 2027, sales are projected to be 2,136 billion yen (+10.9%), continuing domestic and international expansion. Operating profit is expected to be 3.75 billion yen (+6.5%) and net income to be 2.62 billion yen (△6.8%), with continued growth in sight. Proactive investments in facilities and R&D will promote standardization and customization of Chinese herbal medicine treatments. Dividends are planned to increase to 158 yen, maintaining the company's shareholder return policy.
Tsumura & Co.
Company overview · Stock price · Financial data · All IR
